Australia, Feb. 5 -- Bristol-Myers Squibb Co., owns the trademark (2596598) for 'ZYWISPO' till Oct. 21, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.] and 5 [Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease;Antivirals;Antibodies for medical purposes;Biological preparations for the treatment of cancer;Anticoagulants;Stem cells for medical purposes;Radiopharmaceutical preparations for the treatment of cancer and solid tumors;Diagnostic radiopharmaceutical preparations;Diagnostic preparations for medical purposes]
Type of Mark: Word
Date of Acceptance: Oct. 27, 2025
Registration Advertised: Feb. 4
For further details contact Spruson & Ferguson.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2596598.
Disclaimer: Curated by HT Syndication.
